



CONVERSATION RECORD

5/18/15

NAME OF PERSON(S) CONTACTED OR IN CONTACT WITH YOU Clay Cramer, RSO		DATE OF CONTACT 5/7/2015	TYPE OF CONVERSATION <input type="checkbox"/> E-MAIL <input checked="" type="checkbox"/> TELEPHONE <input type="checkbox"/> INCOMING <input checked="" type="checkbox"/> OUTGOING
E-MAIL ADDRESS ccramer@esperion.com		TELEPHONE NUMBER	

ORGANIZATION Esperion Therapeutics, Inc.	DOCKET NUMBER(S) 030-37940
---	-------------------------------

LICENSE NUMBER(S) 21-32115-02	CONTROL NUMBER(S)
----------------------------------	-------------------

SUBJECT  
Esperion: License Termination and Facility Decommission

SUMMARY  
Esperion Therapeutics, Inc. has been an NRC licensee since April 23, 2009. The license authorizes the use of H-3, C-14, P-32 and S-35 in millicurie quantities. According to the RSQ P-32 and S-35 have not been used. The last inspection was performed on February 25, 2015, a clear 591 form was issued. Mr. Cramer requested a conference call to discuss the decommissioning of Esperion's facilities and the subsequent termination of Esperion's NRC license. On the call for the licensee were Clay Cramer, RSO and Larry Kenaga, Senior Safety Consultant for Barr Engineering Co. The individuals representing NRC were Peter Lee, Ph.D. of MCID and Toye Simmons license reviewer for MLB.  
Mr. Cramer stated that licensed activities will end on May 15, 2015. Mr. Kenaga stated that decommissioning of the lab furniture and fixtures will begin shortly after. Chase Environmental Group, Inc. of Oak Ridge, TN has been contracted for the decommissioning effort. The licensee indicated that all decommissioning will be completed by or around June 20th and shortly thereafter the request for termination will be submitted. The RSO indicated that the building lease is up on September 1st and hopes that the termination will be completed by then.  
Dr. Lee requested that the decommissioning plan be provided for his review. Further, he reminded the licensee to play close attention to the sewer and ventilations systems during the decommissioning process.

**Continue on Page 2**

ACTION REQUIRED (IF ANY)  
NONE REQUIRED

**Continue on Page 3**

NAME OF PERSON DOCUMENTING CONVERSATION  
Toye L. Simmons

SIGNATURE  
*Toye L. Simmons*

## Simmons, Toye

---

**From:** Simmons, Toye  
**Sent:** Thursday, May 07, 2015 9:49 AM  
**To:** Pelke, Patricia; Orlikowski, Robert  
**Cc:** Lee, Peter  
**Subject:** Esperion Therapeutics, Inc. license termination

On May 7, 2015, Peter and I had a telephone conversation with Clay Cramer, RSO and Larry Kenaga, a consultant, regarding the proposed termination of Esperion Therapeutics, Inc., Plymouth, Michigan, License No. 21-32115-02 , Docket No. 030-37940. Esperion Therapeutics, Inc. is authorized for carbon-14, hydrogen-3, phosphorus-32 and sulfur-35. According to Mr. Clay, P-32 and S-35 have never been used or purchased under this license. Mr. Clay and Mr. Kenaga briefly described the timetable for the proposed termination. All licensed activities will cease on May 15, 2015 and between that date and on/or about June 20<sup>th</sup> the plan is that decommissioning activities will be completed. The licensee would like to have the license termination completed before September 1<sup>st</sup> when the lease is up. Peter has agreed to review the consultant's plan prior to decommissioning taking place. Since this action involves Class 2 waste, it is recommended that the termination request be handled by MCID.

Toye L. Simmons  
Materials Licensing Branch  
U.S. Nuclear Regulatory Commission  
Region III  
2443 Warrenville Road, Suite 210  
Lisle, IL 60532-4352  
Office: (630) 829-9842  
Fax: (630) 515-1078

